Vicor Technologies, Inc. (OTCBB: VCRT) is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or resulting from inaccurate identification are garnering increased attention in the current health care reform environment.
These populations are significant:
Vicor’s diagnostics are being developed to address those needs easily, accurately, and inexpensively. Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both measure heart rate variability (HRV) for physician-determined use and be used specifically in cardiovascular disease testing. Physicians who have purchased the PD2i Analyzer™ are largely using it to test their diabetic patients for autonomic nervous system (ANS) dysfunction, also known as diabetic autonomic neuropathy or DAN. Cardiologists are using it to test their cardiovascular disease patients to risk stratify them for cardiac death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ to measure HRV to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.
August 2011 – Opus Group Financial
April 2011 – Opus Group Financial
February 2011 – Opus Group Financial
February 2011 – Zaks Equity Research